Quince Therapeutics (NASDAQ:QNCX – Get Free Report) and Senti Biosciences (NASDAQ:SNTI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation. Insider & Institutional Ownership 39.6% of Quince […]
Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) Director David Lamond bought 22,327 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was bought at an average price of $1.02 per share, for a total transaction of $22,773.54. Following the completion of the purchase, the director now directly owns 2,302,291 […]
Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) Director David Lamond bought 19,123 shares of the firm’s stock in a transaction on Tuesday, December 5th. The shares were purchased at an average cost of $1.01 per share, with a total value of $19,314.23. Following the completion of the transaction, the director now owns 2,241,418 shares […]
Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) Director David Lamond bought 19,123 shares of the stock in a transaction on Thursday, December 7th. The stock was purchased at an average price of $1.01 per share, with a total value of $19,314.23. Following the completion of the acquisition, the director now directly owns 2,279,664 shares […]
Quince Therapeutics (NASDAQ:QNCX – Get Free Report) and Prime Medicine (NYSE:PRME – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Analyst Recommendations This is a summary of […]